ADRB2 and respiratory system disorder: These ligands are therefore promising candidates for the development of β-blockers devoid of β2-AR–mediated adverse effects of bronchospasm and vasoconstriction and, thus, may prove beneficial in patients with concomitant cardiovascular and respiratory disease or limb ischemia (peripheral vascular disease).